The World Health Organization (WHO) has backed a Covid-19 treatment developed by Swiss pharmaceutical giant Roche and United States biotech company Regeneron.
This content was published on
2 minutes
swissinfo.ch/mga
Español
es
COVID-19: La OMS aprueba tratamiento Roche/Regeneron
WHO also made it clear that it wants both companies to make the treatment available to low income countries at an affordable price.
Roche and Regeneron have collaborated on producing the treatment using the monoclonal antibodies casirivimab and imdevimab, which have been shown to be effective at neutralising the virus when combined.
WHO on Friday recommended that the treatment be used on infected people who either have underlying health conditions or are suffering from severe symptoms.
The health body has urged both companiesExternal link to “address the high price and limited production” of the treatment. It is asking Roche for “a donation and distribution of the drug through UNICEF”.
The global health agency UNITAID is also negotiating with the manufacturers to grant access to the drug for less well-off countries.
“The need to have effective treatments for Covid-19 has never been greater, with many countries around the world facing case surges driven by Delta and other variants,” UNITAID stated on Friday. “These surges are having a particularly devastating impact on low- and middle- income countries, which continue to have limited access to vaccines.”
The agency welcomed an initial donation from Roche and Regeneron to meet this challenge but argued for a more sustainable solution. “Broader access commitments are needed from industry to ensure that pricing and supply conditions enable this product to reach all people regardless of where they live.”
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
First large-scale alpine solar plant approved in Switzerland
This content was published on
The approval was met with satisfaction by the project's organisers, but it also brings with it a certain amount of pressure.
Medieval squirrels may have ‘helped spread leprosy’
This content was published on
An examination of squirrel remains in the United Kingdom has opened up interesting questions and possibilities in terms of the history of the disease.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche bids to co-develop potential oral Covid-19 treatment
This content was published on
The Basel-based company has partnered with Atea Pharmaceuticals to develop, manufacture and distribute the latter’s oral anti-Covid-19 treatment.
WHO and Roche launch trials of potential coronavirus treatments
This content was published on
Roche is launching a clinical trial of a potential new Covid-19 drug, adding to rapidly growing investments in combating coronavirus.
Chair of pharma firm Roche advocates mandatory Covid-19 vaccination
This content was published on
Christoph Franz said he was in favour of compulsory jabs if vaccination coverage rates were insufficient and if there was a social consensus.
Roche rheumatism drug does not reduce Covid-19 deaths
This content was published on
Swiss pharma firm Roche says a drug normally used to treat other medical conditions has failed to prove its effectiveness at alleviating the symptoms of Covid-19.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.